Effects of functional electrical stimulation of lower limb muscles on circulating endothelial progenitor cells, CD34+ cells and vascular endothelial growth factor-A in heart failure with reduced ejection fraction
Regular aerobic exercise is an indicated therapeutic exercise approach for chronic heart failure (CHF) patients as it improves cardiac output and augments blood flow to the peripheral vascular system. 1 Potential mechanisms underlying beneficial haemodynamic effects of aerobic exercise include enhanced endothelial function, improved responses to vasodilator substances, and induction of angiogenesis. 2 Functional electrical stimulation (FES) of lower limbs appears as an alternative exercise method for patients who cannot engage in conventional exercise training programmes. FES has been associated with beneficial effects in functional status, peak oxygen consumption, endothelial function, muscle mass (type I fibres), quality of life as well as a lower risk for heart failure (HF)-related hospitalizations in CHF patients. 3 Beneficial effects of FES on peripheral muscle function have also been described in stroke and spinal cord injury survivors, coupled with signals of favourable effects on central nervous system plasticity and regeneration processes. Indeed, FES has been shown to induce the expression of neuronal structural proteins in preserved cortex areas adjacent to stroke site as well as to enhance production of progenitor cells in the central nervous system of animal models of stroke or spinal cord injury. 4, 5 Based on the reported effects of FES on neurogenesis, we have hypothesized that its beneficial effects on vascular function in CHF patients may be associated with stimulation of angiogenetic processes. In the present study, we aimed to evaluate the impact of FES on markers of angiogenesis, in relation to functional capacity, echocardiographic parameters and biomarkers in CHF patients.
Our study included 27 consecutive patients, with ischaemic and non-ischaemic CHF with reduced ejection fraction (<40%), who were followed in a CHF outpatient clinic and were clinically stable in New York Heart Association (NYHA) class II-III in the previous 6 months. Exclusion criteria included recent (4 weeks) HF decompensation, recent (<6 weeks) myocardial infarction, unstable angina, acute myocarditis or pericarditis, acute systemic disease (pulmonary emboli, aortic dissection) and cancer of advanced stage. The Institute's Ethics Committee approved the study protocol, all patients gave written informed consent and were randomly assigned to a 6-week FES training programme or placebo. Under the supervision of a chief therapist, eight adhesive electrodes were positioned on the skin over the upper lateral and lower medial aspects of the quadriceps muscle and over the upper and lower portions of the gastrocnemius muscles of both legs. In the FES group, the stimulator was configured to deliver a direct electrical current at 25 Hz for 5 s followed by a 5 s rest. The intensity of the stimulation was adjusted to achieve a visible muscle contraction that was not sufficiently strong to cause discomfort or a significant movement at either the knee or the ankle joints. When the muscles of the right leg were contracted, the muscles of the left leg were relaxing and vice versa. Patients were trained for 30 min a day, 5 days per week for a total of 6 weeks. The placebo group was exposed to the same regimen as the FES group, using a lower intensity of stimulation (5 Hz) that did not lead to visible or palpable contractions, as judged objectively or subjectively. Patient assessment, including history, clinical examination, 6-min walk distance (6MWD), transthoracic echocardiography and blood sampling, was performed before and after completion of either the FES or the placebo protocol. In order to evaluate angiogenesis, levels of vascular endothelial growth factor-A (VEGF-A), CD34+ haematopoietic progenitor cells and endothelial progenitor cells (EPCs) were measured.
The number of CD34+ cells was quantified by flow cytometry according to standardized protocols. 6 EPCs were defined as CD34+ cells co-expressing the glycoprotein antigen AC133+ and vascular endothelial growth factor receptor 2 (VEGFR2+), and were counted from immunomagnetically purified peripheral blood CD34+ cells, as previously described. 7 Determination of VEGF-A expression was performed using an enzymelinked immunosorbent assay (ELISA) as previously reported. 8 Statistical tests were performed using STATA v.13.0 software package (StataCorp LP, College Station, TX, USA). Numeric variables are expressed as median (interquartile range) and categorical variables as number of cases and/or percentage. Changes in numeric variables during treatment were evaluated by linear regression with adjustment for baseline values. Differences in categorical variables were compared using chi-squared test or Fisher's exact test, as appropriate. Correlations between numerical variables were tested with Spearman correlation. A P-value of <0.05 was considered as indicative of statistical significance. Post-hoc power calculation showed that study had a 100% power to detect the observed difference in 6MWD at an alpha level of 0.05.
A total of 27 patients (22 male) aged from 55 to 82 years were enrolled in the study. At baseline, no significant differences were observed between the two study groups regarding demographics, co-morbidities, functional status (NYHA class and 6MWD), main laboratory and echocardiographic findings. Regarding laboratory indices of angiogenesis, EPCs were significantly higher in the placebo group (P = 0.003), while other indices did not differ significantly. Both groups adhered strongly to the protocol without drop-outs. No adverse events were recorded, and none of the patients were hospitalized for HF during the study period. The effects of FES or placebo on study parameters are shown in Table 1 . There was a significant increase in VEGF-A in the FES group compared to the placebo group [mean Δ (standard error): 98.7 pg/mL (21.6) vs. 3.1 (12.5), P adjusted for baseline values =0.002]. Also, there was a trend towards a greater increase in EPCs in the FES vs. placebo group [5.3% of CD34+ (1.4) vs. 0.1 (0.8), P = 0.092] and a trend towards an increase in CD34+ cells in the FES group [2572.7 cells/mL (1119.7)] with a respective decrease in the placebo group [-852.9 (1278.6), P = 0.060]. In addition, in the FES group a significant improvement in NYHA class (P < 0.001), an increase in 6MWD (P < 0.001) and a decrease in B-type natriuretic peptide (P < 0.001) and E/E' ratio (P < 0.001) were observed compared to the placebo group. Observed changes in VEGF-A and EPCs correlated significantly with changes in 6MWD (rho = 0.549, P = 0.003; rho = 0.684, P < 0.001, respectively), while changes in CD34+ cells correlated significantly with changes in 6MWD (rho = 0.648, P < 0.001) and E/E' (rho = -0.597, P = 0.001).
In conclusion, preliminary evidence suggests that, in parallel to improving exercise capacity and central haemodynamics in CHF, FES may promote angiogenesis and ameliorate endothelial function in peripheral muscles. These findings may support the use of FES as the preferred exercise modality in patients with significant permanent limitations to physical exercise or as a bridging modality until physical exercise is possible. Conflict of interest: none declared.
